RNA-Seq study of skin and blood samples from prospectively-recruited, deeply-phenotyped discovery and refinement psoriasis cohorts, during targeted treatment with adalimumab or ustekinumab

ABSTRACT: The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium, prospectively recruited deeply-phenotyped discovery and refinement psoriasis patient cohorts, during the early phase of treatment with two distinct biologics, adalimumab (TNF inhibitor) and ustekinumab (IL-12/23 inhibitor). Utilising this large multi-dimensional dataset, we aimed to identify transcripts associated with specific disease endotypes, defined by clinical and phenotypic features before commencing treatment (baseline); and disease severity endotypes, defined by Psoriasis Area and Severity Index (PASI)-associated gene expression profiles

INSTRUMENT(S): Illumina HiSeq 2500

ORGANISM(S): Homo sapiens

SUBMITTER: Michael Barnes 

PROVIDER: E-MTAB-14509 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress